gambogic-acid and Hypoxia

Phototherapy is a promising strategy for cancer therapy by reactive oxygen species (ROS) of photodynamic therapy (PDT) and hyperthermia of photothermal therapy (PTT). However, the therapeutic efficacy was restricted by tumor hypoxia and thermal resistance of increased expression of heat shock protein (Hsp). In this study, we developed albumin nanoparticles to combine hypoxia relief and heat shock protein inhibition to overcome these limitations for phototherapy enhancement.. Near-infrared photosensitizer (IR780) and gambogic acid (GA, Hsp90 inhibitor) were encapsulated into albumin nanoparticles via hydrophobic interaction, which was further deposited MnO. This study develops a facile approach to co-deliver IR780 and GA with self-assembled albumin nanoparticles, which could relive hypoxia and suppress Hsp for clinical application of cancer phototherapy.

Topics: Animals; Antineoplastic Agents; Cell Survival; Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Hydrophobic and Hydrophilic Interactions; Hypoxia; Infrared Rays; Male; Manganese Compounds; Mice; Mice, Inbred BALB C; Nanoparticles; Oxides; Photosensitizing Agents; Phototherapy; Tumor Microenvironment; Xanthones